Scientific title as of 21/09/2018: RAndomised IroN Deficiency anaemia management Pilot Previous scientific title: Oral iron, intravenous iron or discontinuation of therapy for older adults with treatment unresponsive iron deficiency anaemia: a pilot randomised controlled trial

niversity of Aberdeen0 个研究点目标入组 5 人开始时间: 2017年8月16日最近更新: 2022年10月17日

适应症

试验速览

暂无简介。

•1. Age 65 years or over
•2. Haemoglobin of >=85g/L and <=110g/L prior to commencing oral iron
•3. Ferritin <100µg/L prior to commencing oral iron
•4. Currently taking oral iron at any dose with a minimum of 8 weeks therapy
•5. Insufficient response to oral iron therapy (sufficient response defined as improvement in Hb of 20g/L after a minimum of 8 weeks of oral iron therapy)
•6. Relevant investigations (including upper and lower GI endoscopies) either already conducted, offered but declined by the patient, or deemed not appropriate by the treating clinician

•1. Active GI cancers
•2. Active (unhealed) peptic ulcer disease
•3. No ferritin level performed prior to commencing oral iron
•3. Bleeding disorders (including being on oral anticoagulants; antiplatelet agents are permitted)
•4. Weight loss of >5Kg in the last 3 months (as a possible marker of occult cancer)
•5. Estimated GFR of <30ml/min/1.73m2 by CKD-EPI equation
•6. Symptomatic chronic heart failure (defined according to the European Society of Cardiology guidelines; note asymptomatic left ventricular systolic dysfunction is not classed as heart failure)
•7. Terminal illness (with life expectancy less than 3 months as deemed by the local investigator)
•8. Severe cognitive impairment precluding written informed consent
•9. Unable to mobilise without human assistance (walking aids are allowed)
•10. Previous reaction to intravenous iron
•11. Currently participating in, or within 30 days of completion of, another clinical trial

发起方

niversity of Aberdeen